Regulatory Filings • Nov 28, 2012
Regulatory Filings
Open in ViewerOpens in native device viewer
Press Release
Nantes, Lyon (France) – November 28th, 2012 − VIVALIS (NYSE Euronext: VLS), a biopharmaceutical company, announced today that it has been awarded the Prix de la Relation Actionnaires (Prize for Investor Relations) in the Small Caps category. Organized by the Les Echos Group and Mazars, in the presence of Jérôme Cazuhac, Budget Secretary of State for France, this prize rewards listed companies in Paris with the best practices for financial communication towards retail and institutional investors.
Franck Grimaud, CEO, and Majid Mehtali, CSO, co-managers of VIVALIS jointly stated, " We are very proud to receive the Prix de la Relation Actionnaires. Our listing has given us the ability to transform and evolve from a young innovative SME into an international actor, which EB66® technology is now a reference for the production of vaccines. This success results from the unique expertise of our teams as well as the support of our shareholders that choose to trust us. We owe them a financial communication of quality. This is a commitment that applies to all our shareholders regardless of their size, location, and how long they have been with us. This prize is the opportunity to thank all our shareholders again for their support and to reiterate VIVALIS' aggressive ambitions. These ambitions will come with financial communications that are always more proactive ."
January 15th, 2013, after NYSE Euronext market closing: 2013 Financial calendar
Vivalis (NYSE-Euronext: VLS) is a biopharmaceutical company that provides innovative cell-based solutions to the biotechnology and pharmaceutical industry for the manufacture of vaccines and recombinant proteins, and develops monoclonal antibodies for the prevention and treatment of diseases with unmet medical needs. Vivalis' expertise and intellectual property are leveraged in two main areas: roteins, licenses for its EB66®
Vivalis offers research and commercial licenses cells, to pharmaceutical and biotechnology companies for the production of therapeutic and prophylactic viral vaccines, virosomes, VLPs and recombinant proteins, including monoclonal antibodies. Cl EB66® produced vaccines are currently on EB66® cells received market approval in Japan for use in animal health. receives an upfront payment, clinical stage milestone payments along with royalties on licensees' net sales. cell line, derived from duck embryonic stem on-going in the USA and Japan and in 2012 a vaccine produced in Through these programs, Vivalis Clinical trials of
Customized solutions for the discovery, development and production of rare, fully human monoclonal antibodies are offered by Vivalis. Through these programs, Vivalis receives payments associated with the funding of discovery research, an upfront payment, clinical stage milestone payments along with royalties on net sales of licensed antibodies that are commercially developed from the inical is. use of the platform.
Based in Nantes and Lyon (France) and in Toyama (Japan), Vivalis was founded in 1999 by the Group Grimaud (approx. 1,700 employees), one of the worldwide leaders in animal genetic selection. Vivalis has established more than 30 partnerships and licenses with world leaders in biopharmaceutical industry, including Sanofi Pasteur, GlaxoSmithKline Biologicals, Transgene, Pfizer Animal Health, Kaketsuken, Kitasato Daiichi Sankyo Vaccine, Merial, Merck Animal Health and SAFC Biosciences. Vi French ATLANTIC BIOTHERAPIES and LYON BIOPOLE bio INNOVATION CLUSTER FOR HEALTH SCIENCE based in Toyama. erships Vivalis is a member of the bio-clusters and a member of the Japanese HOKURIKU going valis clusters
VIVALIS Listed on Euronext Paris Reuters: VLS.PA – Bloomberg: VLS FP Included in NYSE Euronext's SBF 250, CAC Small 90 and Next Biotech indexes – Compartment C of NYSE Euronext
This document contains forward-looking statements and comments on the company's objectives and strategies. No guarantee can be given to any of the events anticipated by the forward contained in this document, which are subject to inheren company's Document de Référence in which the company operates. looking inherent risks, including risk factors described in the , changes in economic conditions, the financial markets or the markets forward-looking statements t
VIVALIS Franck Grimaud, CEO Email: [email protected]
Financial communications Axelle Vuillermet / Pierre Laurent Tél.: +33 (0) 1 44 71 94 93 Email : [email protected] agency
Building tools?
Free accounts include 100 API calls/year for testing.
Have a question? We'll get back to you promptly.